Take a look through some of the notable data presentations at this year's ESMO Congress.
|Videos|September 24, 2021
Dr. Gao on treating re-emerged PARPi-resistant prostate cancer
Author(s)Urology Times staff
“Some potential…combination therapy may be valuable, such as combining with a checkpoint inhibitor or some target senescence because this resistance involves those kinds of mechanisms,” says Allen C. Gao, MD, PhD.
Advertisement
In this video, Allen C. Gao, MD, PhD, discusses the possibility of re-emerged PARP inhibitor resistant prostate cancer and what future studies should do to continue developing treatments. Gao was the senior author on the study, “
Gao is the Ralph de Vere White professor in the department of urologic surgery and director of urologic research at University of California, Davis.
Advertisement
Related to this article
Advertisement
Advertisement
Trending on Urology Times
1
How PSMA-PET shapes staging and recurrence workup in prostate cancer
2
European Commission approves perioperative pembrolizumab plus enfortumab vedotin for MIBC
3
FDA accepts new drug application for UGN-103 in recurrent LG-IR-NMIBC
4
Engy Habashy, MD, on the role of androgens in GSM management
5